Adial Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, and Tedor Pharma, a full-service contract development and manufacturing organization (CDMO), have entered into a collaboration agreement to provide cGMP contract manufacturing services for AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD).   Adial is on track to commence its first phase 3 trial of AD04 next quarter and plans to cond...